A Phase 1, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of CC-220 and to Evaluate the Relative Bioavailability of a Formulated CC-220 Capsule in Healthy Subjects
Latest Information Update: 03 Feb 2022
At a glance
- Drugs Iberdomide (Primary) ; Pneumococcal vaccine; Tetanus toxoid
- Indications Multiple myeloma; Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 22 Jan 2014 New trial record